Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 50.65 as of 2026-10-06T15:06:33.279Z.
Consensus retrieved: 2026-10-06T11:16:08.731Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:06:33.279Z.
Quote observation: 2026-10-06T15:05:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 964f8bcea024e80fb52d816f3b4380b7088b93770ce31cf7c1083d390364c537
Forward PE Ratio (50.65) = Dated Quote Price ($55.09) / Consensus Forward EPS ($1.09)
FORWARD PE RATIO
50.65
SECTOR MEDIAN · HEALTHCARE
18.82
median of 161 covered companies
CURRENT VS SECTOR MEDIAN
+169.13%
vs the sector median at left
Eton Pharmaceuticals, Inc.
Market Cap
$1.51B
Forward PE Ratio
50.65
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Eton Pharmaceuticals, Inc. (ETON) | $1.51B | 50.65 |
| Nutex Health, Inc. (NUTX)vs › | $1.52B | 7.93 |
| Phibro Animal Health Corporation (PAHC)vs › | $1.50B | 10.59 |
| Innoviva, Inc. (INVA)vs › | $1.54B | 8.61 |
| Certara, Inc. (CERT)vs › | $1.48B | 27.96 |
| GH Research PLC (GHRS)vs › | $1.47B | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.47B | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 17.77 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A |
| Omnicell, Inc. (OMCL)vs › | $1.58B | 15.34 |
Trailing P/E
143.2
reported TTM EPS
Forward P/E
50.6
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.09 implies +186.8% EPS growth vs the reported trailing $0.38.
At the dated quote price of $55.09, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.09 | $1.03 – $1.14 | 2 | 50.7x |
| 2027-12-31 | $2.10 | $1.80 – $2.39 | 2 | 26.2x |
| 2028-12-31 | $3.12 | $2.62 – $3.70 | 4 | 17.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
